Abstract:
The present invention relates to a mutant expandase that is a variant of a model polypeptide with expandase activity whereby the mutant expandase has an at least 2.5-fold improved in vitro expandase activity towards adipyl-6-APA in comparison with a model polypeptide with expandase activity.
Abstract:
The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C.
Abstract:
The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C.
Abstract:
The present invention relates to a mutant expandase that is a variant of a model polypeptide with expandase activity whereby the mutant expandase has an at least 2-fold improved in vitro expandase activity towards adipyl-6-APA in comparison with the model polypeptide with expandase activity.
Abstract:
The present invention relates to a mutant expandase that is a variant of a model polypeptide with expandase activity whereby the mutant expandase has an at least 2-fold improved in vitro expandase activity towards adipyl-6-APA in comparison with the model polypeptide with expandase activity.
Abstract:
Una expandasa mutante que es una variante de un polipéptido modelo con actividad de expandasa mediante laque la treonina en la posición 89 de aminoácido en el péptido modelo se ha sustituido por lisina usando lanumeración de las posiciones de aminoácido de la secuencia de aminoácidos de la enzima expandasa como serepresenta en SEC ID NO: 1, y mediante la cual el polipéptido modelo con actividad de expandasa tiene lasecuencia de aminoácidos como se representa en SEC ID NO: 1, o una secuencia de aminoácidos que tiene almenos 70% de identidad con SEC ID NO: 1.
Abstract:
The present invention relates to a method for the production of a compound of interest by microbial fermentation, wherein the microbial host cell used has been modified in its genome such that it results in a deficiency in the production of at least one non-ribosomal peptide synthase. The present invention further relates to a microbial host cell that has been modified in its genome such that it results in a deficiency in the production of at least one non-ribosomal peptide synthase. The invention further relates to a compound of interest.